AR037647A1 - Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina - Google Patents

Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina

Info

Publication number
AR037647A1
AR037647A1 ARP030101848A ARP030101848A AR037647A1 AR 037647 A1 AR037647 A1 AR 037647A1 AR P030101848 A ARP030101848 A AR P030101848A AR P030101848 A ARP030101848 A AR P030101848A AR 037647 A1 AR037647 A1 AR 037647A1
Authority
AR
Argentina
Prior art keywords
treatment
derivatives
diseases
diarylurea derivatives
diarylurea
Prior art date
Application number
ARP030101848A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0212413A external-priority patent/GB0212413D0/en
Priority claimed from GB0305684A external-priority patent/GB0305684D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR037647A1 publication Critical patent/AR037647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Uso de derivados de diarilurea en el tratamiento de enfermedades dependientes de la cinasa de proteína, o para la fabricación de composiciones farmacéuticas para utilizarse en el tratamiento de estas enfermedades, a métodos de uso de los derivados de diarilurea en el tratamiento de estas enfermedades, a preparaciones farmacéuticas que comprenden los derivados de diarilurea para el tratamiento de estas enfermedades, a derivados de diarilurea para utilizarse en el tratamiento de estas enfermedades, a novedosos derivados de diarilurea, a preparaciones farmacéuticas que comprenden estos derivados de diarilurea novedosos, a procesos para la fabricación de los derivados de diarilurea novedosos, al uso o método de uso de los derivados de diarilurea novedosos como se menciona anteriormente, y/o a estos derivados de diarilurea novedosos para utilizarse en el tratamiento del cuerpo animal o humano. Reivindicación 1: El uso de un derivado de diarilurea de la fórmula (1): en donde G no está presente, o es alquileno inferior o cicloalquileno de 3 a 5 átomos de carbono, y Z es un radical de la fórmula (2): ó G no está presente y Z es un radical de la fórmula (3): A es CH, N ó N->O, y A' es N ó N->O, con la condición de que no más de uno de A y A' puede ser N->O; n es 1 ó 2; m es 0, 1, ó 2; p es 0, 2, ó 3; r es de 0 a 5; X es NR si p es 0, en donde R es hidrógeno o una fracción orgánica, o si p es 2 ó 3, X es nitrógeno que, junto con (CH2) p y los enlaces representados en las líneas punteadas (interrumpidas) (incluyendo los átomos con los que están enlazados) forma un anillo, o X es CHK, en donde K es alquilo inferior o hidrógeno, y p es 0, con la condición de que los enlaces representados en las líneas punteadas, si p es 0, están ausentes; Y1 es O, S, ó CH2; Y2 es O, S, ó NH; con la condición de que (Y1)n-(Y2)m no incluye grupos O-O, S-S, NH-O, NH-S, ó S-O cada uno de R1, R2, R3, y R5, independientemente de los otros, es hidrógeno o una fracción inorgánica u orgánica, o cualesquiera dos de ellos forman juntos un puente de alquilendioxilo inferior enlazado por medio de los átomos de oxígeno, y la restante de estas fracciones es hidrógeno o una fracción inorgánica u orgánica; y R4 (si está presente, es decir, si r no es 0) es una fracción inorgánica u orgánica; o un tautómero del mismo; o una sal farmacéuticamente aceptable del mismo; para la fabricación de composiciones farmacéuticas para utilizarse en el tratamiento de enfermedades dependientes de la cinasa de proteína.
ARP030101848A 2002-05-29 2003-05-27 Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina AR037647A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0212413A GB0212413D0 (en) 2002-05-29 2002-05-29 Organic Compounds
GB0305684A GB0305684D0 (en) 2003-03-12 2003-03-12 Organic compounds
GB0309219 2003-04-23

Publications (1)

Publication Number Publication Date
AR037647A1 true AR037647A1 (es) 2004-12-01

Family

ID=29587403

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101848A AR037647A1 (es) 2002-05-29 2003-05-27 Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina

Country Status (21)

Country Link
US (1) US7652022B2 (es)
EP (1) EP1511730B8 (es)
JP (1) JP4608312B2 (es)
KR (1) KR101036394B1 (es)
CN (1) CN1656073B (es)
AR (1) AR037647A1 (es)
AT (1) ATE417037T1 (es)
AU (1) AU2003242591B2 (es)
BR (1) BR0311313A (es)
CA (1) CA2484288A1 (es)
DE (1) DE60325209D1 (es)
ES (1) ES2318158T3 (es)
IL (1) IL164784A0 (es)
MX (1) MXPA04011789A (es)
NO (1) NO20045521L (es)
NZ (1) NZ536781A (es)
PE (1) PE20040522A1 (es)
PL (1) PL372426A1 (es)
PT (1) PT1511730E (es)
TW (1) TW200406374A (es)
WO (1) WO2003099771A2 (es)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
PL376372A1 (en) * 2002-08-08 2005-12-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078128A2 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
PT1660057E (pt) 2003-08-27 2012-08-02 Ophthotech Corp Terapia de associação para o tratamento de distúrbios neovasculares oculares
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
EP1689376A2 (en) * 2003-11-28 2006-08-16 Novartis AG Diaryl urea derivatives in the treatment of protein kinase dependent diseases
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CA2554878A1 (en) * 2004-01-30 2005-08-18 Merck Patent Gmbh Bisarylurea derivatives
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
EP1765327B1 (en) 2004-06-17 2014-08-13 Cytokinetics, Inc. Compounds, compositions and methods
AU2011253934C1 (en) * 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
EP1802591B1 (en) 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
WO2006040056A1 (en) * 2004-10-13 2006-04-20 Merck Patent Gmbh Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
CN101106983A (zh) * 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
US7300931B2 (en) 2004-12-28 2007-11-27 Kinex Pharmaceuticals, Llc Compositions for treating cell proliferation disorders
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EA026785B1 (ru) 2005-05-10 2017-05-31 Инсайт Холдингс Корпорейшн Модуляторы индоламин 2,3-диоксигеназы и способы их применения
MY146795A (en) * 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
GT200600207A (es) * 2005-06-09 2007-01-15 Novartis Ag Proceso para la síntesis de compuestos orgánicos
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006282456C1 (en) * 2005-08-24 2012-10-04 Eisai R & D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (3)
GT200600411A (es) 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US7795279B2 (en) 2005-10-18 2010-09-14 Janssen Pharmaceutica Nv Method of inhibiting FLT3 kinase
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
CA2633411A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
GB0605120D0 (en) * 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
RU2481840C2 (ru) 2006-04-07 2013-05-20 Новартис Аг КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
SI2021335T1 (sl) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2564781T3 (es) 2006-04-20 2016-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la c-fms quinasa
EP2041071B1 (en) * 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
KR101380444B1 (ko) * 2006-08-23 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 염 또는 그 결정 및 이들의 제조 방법
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2102173B1 (en) * 2006-12-22 2010-10-20 F. Hoffmann-La Roche AG Pyrimidyl derivatives as protein kinase inhibitors
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
JP5635398B2 (ja) 2007-04-16 2014-12-03 ハッチソン メディファーマ エンタープライジズ リミテッド ピリミジン誘導体
CN101687801B (zh) 2007-04-17 2012-10-03 诺瓦提斯公司 用作癌症治疗的萘甲酸酰胺的醚
US8143293B2 (en) * 2007-04-20 2012-03-27 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2009009041A2 (en) * 2007-07-06 2009-01-15 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009051822A1 (en) * 2007-10-19 2009-04-23 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
MY152948A (en) 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
JPWO2009104520A1 (ja) * 2008-02-18 2011-06-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法（２）
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2274288A2 (en) 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
DK2824100T3 (en) 2008-07-08 2018-04-16 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101671301B (zh) * 2009-05-05 2014-02-26 江苏省药物研究所有限公司 杂环取代的二苯脲类衍生物及其用途
PE20120371A1 (es) 2009-05-22 2012-05-17 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
US20120202818A1 (en) * 2009-06-09 2012-08-09 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120157482A1 (en) * 2009-08-28 2012-06-21 Graves Iii Alan Peterson Compounds and methods
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN101717373B (zh) * 2009-11-09 2012-06-20 东南大学 二芳基脲类衍生物及其用途
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
WO2011092469A1 (en) * 2010-02-01 2011-08-04 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
KR101836538B1 (ko) 2010-02-18 2018-03-08 인사이트 홀딩스 코포레이션 야누스 키나아제 억제제로서의 사이클로부탄 및 메틸사이클로부탄 유도체
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
KR20130044382A (ko) * 2010-03-01 2013-05-02 마이렉시스 인코포레이티드 화합물 및 그의 치료 용도
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
KR102040479B1 (ko) 2010-05-21 2019-11-06 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
BR112013020798B1 (pt) 2011-02-18 2022-03-15 Incyte Corporation Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
BR112013032720A2 (pt) 2011-06-20 2016-09-13 Incyte Corp "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8841301B2 (en) 2011-09-26 2014-09-23 Bristol-Myers Squibb Company Selective NR2B antagonists
US8722670B2 (en) 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014007951A2 (en) 2012-06-13 2014-01-09 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CA2883172A1 (en) * 2012-08-29 2014-03-06 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
HUE037637T2 (hu) 2012-08-30 2018-09-28 Athenex Inc N-(3-fluorobenzil)-2-(5-(4-morfolinofenil)piridin-2-IL) acetamid, mint fehérje tirozin kináz modulátorok
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
CN103804349A (zh) * 2012-11-01 2014-05-21 杨子娇 一类治疗青光眼的化合物及其用途
AU2013344780B2 (en) 2012-11-15 2018-03-01 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
RS58547B1 (sr) 2013-03-06 2019-05-31 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
KR102340654B1 (ko) 2013-04-02 2021-12-16 옥슬러 액퀴지션즈 리미티드 키나제 저해제
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
SI3231801T1 (sl) 2013-05-17 2019-05-31 Incyte Corporation Bipirazolna sol kot inhibitor JAK
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
AU2014309017A1 (en) 2013-08-20 2016-03-10 Incyte Corporation Survival benefit in patients with solid tumors with elevated C-reactive protein levels
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
CA2934199A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
SG11201607083VA (en) 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
DK3129021T3 (da) 2014-04-08 2020-11-09 Incyte Corp Behandling af b-celle-maligniteter ved en kombination af jak- og pi3k-inhibitorer
CN104974132B (zh) * 2014-04-08 2017-05-17 北大方正集团有限公司 多取代的吡啶化合物、制备方法、用途及药物组合物
TW201625643A (zh) 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3174859B1 (en) 2014-07-31 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EA033544B1 (ru) 2014-09-10 2019-10-31 Glaxosmithkline Ip Dev Ltd Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
SG11201706917WA (en) 2015-02-27 2017-09-28 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
KR20170122809A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US11078541B2 (en) 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
EP3624780A1 (en) 2017-05-17 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
JP7021356B2 (ja) * 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
JP2021513981A (ja) 2018-02-16 2021-06-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ サイトカイン関連障害を治療するためのｊａｋ１経路阻害薬
JP2021515036A (ja) 2018-02-27 2021-06-17 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
PL3762368T3 (pl) 2018-03-08 2022-06-06 Incyte Corporation ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11584961B2 (en) 2018-03-30 2023-02-21 Incyte Corporation Biomarkers for inflammatory skin disease
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
DK3847175T3 (da) 2018-09-05 2024-03-18 Incyte Corp Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
SG11202108702XA (en) 2019-02-15 2021-09-29 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
JP2022545568A (ja) 2019-06-10 2022-10-27 インサイト・コーポレイション Ｊａｋ阻害剤による白斑の局所治療
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3148776A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
EP4021907A1 (en) 2019-08-26 2022-07-06 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
BR112022006977A2 (pt) 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
JP2023506118A (ja) 2019-10-16 2023-02-15 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022010860A (es) 2020-03-06 2022-12-02 Incyte Corp Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1.
US20210355121A1 (en) 2020-04-16 2021-11-18 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
PE20231102A1 (es) 2020-06-02 2023-07-19 Incyte Corp Procesos para preparar un inhibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220064188A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US20230364095A1 (en) 2020-09-16 2023-11-16 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2022306671A1 (en) 2021-07-07 2024-01-25 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US20230151005A1 (en) 2021-09-21 2023-05-18 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
US20230143938A1 (en) 2021-10-01 2023-05-11 Incyte Corporation Pyrazoloquinoline kras inhibitors
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
US20230203010A1 (en) 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20230183251A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20230192722A1 (en) 2021-12-22 2023-06-22 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US20230279004A1 (en) 2022-03-07 2023-09-07 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN115108998B (zh) * 2022-07-19 2023-06-30 重庆医科大学 用于抗乙型肝炎病毒的化合物及其应用
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015043A1 (en) * 1992-01-24 1993-08-05 Yoshitomi Pharmaceutical Industries, Ltd. Arylalkananilide compound and pharmaceutical use thereof
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
CZ301102B6 (cs) 1997-12-22 2009-11-04 Bayer Corporation Substituované arylmocoviny, farmaceutické prípravky je obsahující a jejich použití
JP3887769B2 (ja) * 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
PA8489701A1 (es) * 1999-01-13 2002-11-18 Bayer Corp Ureas difenil-(w-carboxiaril substituidas como inhibidores de raf quinasa
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP3712393B2 (ja) * 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
US6706751B2 (en) 2000-12-21 2004-03-16 Hoffman-La Roche Inc. Dihydroindole and tetrahydroquinoline derivatives
WO2004037789A2 (en) 2002-10-24 2004-05-06 Merck Patent Gmbh Methylene urea derivatives as raf-kinase inhibitors
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla

Also Published As

Publication number Publication date
PE20040522A1 (es) 2004-09-28
TW200406374A (en) 2004-05-01
KR20050006281A (ko) 2005-01-15
CN1656073A (zh) 2005-08-17
JP2005527622A (ja) 2005-09-15
CA2484288A1 (en) 2003-12-04
US20060128734A1 (en) 2006-06-15
NO20045521L (no) 2004-12-17
ES2318158T3 (es) 2009-05-01
NZ536781A (en) 2007-12-21
EP1511730A2 (en) 2005-03-09
IL164784A0 (en) 2005-12-18
AU2003242591B2 (en) 2007-07-26
US7652022B2 (en) 2010-01-26
EP1511730B1 (en) 2008-12-10
PL372426A1 (en) 2005-07-25
MXPA04011789A (es) 2005-03-31
WO2003099771A3 (en) 2004-04-01
JP4608312B2 (ja) 2011-01-12
WO2003099771A2 (en) 2003-12-04
ATE417037T1 (de) 2008-12-15
DE60325209D1 (de) 2009-01-22
EP1511730B8 (en) 2009-04-08
PT1511730E (pt) 2009-02-18
CN1656073B (zh) 2010-05-26
BR0311313A (pt) 2005-02-15
KR101036394B1 (ko) 2011-05-23
AU2003242591A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
AR037647A1 (es) Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
AR047496A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
HUP0203803A2 (hu) Neurodegenerációs betegségek kezelésére alkalmazható pirido-pirimidinon-származékok
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
EA200400550A1 (ru) Бициклические производные оксопиридина и оксопиримидина
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
CY1108746T1 (el) Παραγωγα 2-φαινοξυ- και 2-φαινυλοσουλφοναμιδιου με ανταγωνιστικη δραστικοτητα ccr3 για την θεραπεια του ασθματος και αλλων φλεγμονωδων ή ανοσολογικων διαταραχων
CY1105579T1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
PE20081370A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
AR015176A1 (es) Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
EA200100970A1 (ru) Аминопроизводные как ингибиторы протеазы
PE20110995A1 (es) DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
CY1110676T1 (el) ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ
CY1106748T1 (el) Ν-(3,3-dimethylindolin-6-yl){2-[(4-pyridylmethyl) amino}(3-pyridyl)}carboxamide και φαρμακευτικες συνθεσεις της
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
HUP0400963A2 (hu) Antidiarrheás és perifériális analgetikus hatású helyettesített ciklohexán-1,4-diamin-származékok felhasználása gyógyszerkészítmények előállítására
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EA200600513A1 (ru) Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
AR008177A1 (es) Nuevas bisindolilmaleimidas, sales de las mismas, procesos para su preparacion intermediarios, su uso para la fabricacion de medicamentos, metodode tratamiento y composicion farmaceutica.
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal